# United Health Products, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/United Health Products, Inc.). ## Overview United Health Products, Inc. develops and markets patented hemostatic gauze products for wound care and surgical bleeding control. The company is based in the United States and operates through its CelluSTAT product line and related branded formats, with manufacturing and packaging performed through contract and service providers. ## Products & services • CelluSTAT hemostatic gauze • CelluSTAT Gauze for bleeding control • Patented cotton-based wound care materials • Contract-manufactured, sterilized gauze products • Branded product formats: HemoStrip, HEMOSTYP, Nik Fix - **Hemostatic gauze** (70%) — Cotton-based gauze designed to absorb drainage and help control bleeding. - **Wound care dressings** (20%) — Superficial wound and external bleeding products used in healthcare settings. - **Branded surgical/wound formats** (10%) — Product formats and trademarks associated with the company’s gauze platform. - CelluSTAT hemostatic gauze - CelluSTAT Gauze for bleeding control - Patented cotton-based wound care materials - Contract-manufactured, sterilized gauze products - Branded product formats: HemoStrip, HEMOSTYP, Nik Fix ## Customers The company’s target customers are healthcare providers that need products for bleeding control and wound management, especially hospitals, surgery centers, clinics, and physicians. Its stated commercial focus also includes the broader human surgical market, where Class III-approved hemostatic agents are used in more demanding procedures. - **Hospitals and surgery centers** (primary) — Buy hemostatic gauze for internal surgical bleeding control and procedural use. - **Clinics and physicians** (secondary) — Use the products for superficial wounds, drainage absorption, and external bleeding. - **Medical technology partners** (primary) — May commercialize, distribute, or acquire the product platform. - **Surgical device and wound care companies** (primary) — Potential channel partners or strategic buyers for the product line. - Hospitals and surgery centers using hemostatic products in procedures - Clinics and physicians treating superficial wounds and bleeding - Surgical device and wound care partners for commercialization - Medical technology companies interested in distribution or acquisition - Potential Class III surgical users if FDA approval is obtained ## Geography The company is based in the United States, where its products are cut, packaged, and sterilized by service providers. Its stated commercial opportunity includes both domestic and international Class III human surgical markets, although the disclosed operating footprint in the excerpts is primarily U.S.-based. - United States is the core operating and manufacturing base - Cutting, packaging, and sterilization are performed in the U.S. - Commercial opportunity is framed around U.S. and international surgery markets - No country-level revenue disclosure was provided in the excerpts - Geographic exposure is tied to FDA approval and market access ## Strategy The company is focused on obtaining FDA pre-market approval for its CelluSTAT hemostatic gauze so it can address higher-value surgical markets. It is also evaluating commercialization partnerships, a sale, or a merger with an industry participant rather than building a large independent sales organization. - **Obtain FDA PMA for CelluSTAT** (short-term) — Regulatory approval is the key gate to the company’s intended surgical market expansion. - **Secure commercialization partner** (short-term) — A partner can provide distribution, market access, and execution capacity. - **Maximize value through strategic transaction** (medium-term) — Management has indicated a sale or merger may be the preferred long-term path. - Seek FDA PMA for CelluSTAT to access Class III surgical markets - Target premium-priced hemostatic use cases in human surgery - Pursue commercial partnerships with established market participants - Evaluate sale or merger with a wound care or surgical device leader - Use contract manufacturing and service providers to support scale ## Risks The company faces substantial regulatory risk because its core growth plan depends on FDA PMA approval, which cannot be assured. It also has going-concern and financing risk, since it has not yet generated operating revenue and depends on external funding to support development and regulatory work. - **FDA PMA not granted** [critical] — The company’s surgical market strategy depends on approval for Class III use. - **Going-concern and liquidity constraints** [critical] — The company has not yet reached operating scale sufficient to fund overhead internally. - **Dilution from equity financing** [high] — Future capital raises may be needed to fund regulatory and commercialization efforts. - **Commercial execution dependence on partners** [high] — The company does not intend to fully commercialize independently. - **Competition in hemostatic and surgical device markets** [medium] — Established competitors may have stronger regulatory, sales, and hospital relationships. - FDA PMA may be delayed or denied - Going-concern risk due to limited operating scale - Dependence on external financing and dilutive capital - Commercialization may depend on third-party partners - Competition from established hemostatic product makers ## Accounting The most important accounting issue is stock-based compensation, which can materially affect reported expenses for a development-stage company. Investors should also watch estimates tied to going-concern disclosures, financing instruments, and any future valuation judgments if the company raises capital or enters strategic transactions. - **Stock-based compensation** — Operating expenses and equity dilution - **Going-concern assessment** — Disclosure risk and financial statement presentation - **Fair value of financing instruments** — Liabilities, equity, and financing costs - Stock-based compensation affects operating expense and equity dilution - Going-concern assessment reflects financing and liquidity assumptions - Related-party and equity financing terms may affect valuation - No off-balance-sheet arrangements were disclosed - Future transaction accounting could affect asset and liability values --- *Last updated: 2026-04-29T05:06:11.026975+00:00*